1. Home
  2. CRDL vs BHST Comparison

CRDL vs BHST Comparison

Compare CRDL & BHST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRDL
  • BHST
  • Stock Information
  • Founded
  • CRDL 2017
  • BHST 2007
  • Country
  • CRDL Canada
  • BHST Canada
  • Employees
  • CRDL N/A
  • BHST N/A
  • Industry
  • CRDL Biotechnology: Biological Products (No Diagnostic Substances)
  • BHST
  • Sector
  • CRDL Health Care
  • BHST
  • Exchange
  • CRDL Nasdaq
  • BHST Nasdaq
  • Market Cap
  • CRDL 112.4M
  • BHST 106.0M
  • IPO Year
  • CRDL N/A
  • BHST N/A
  • Fundamental
  • Price
  • CRDL $1.44
  • BHST $7.58
  • Analyst Decision
  • CRDL Strong Buy
  • BHST Strong Buy
  • Analyst Count
  • CRDL 2
  • BHST 2
  • Target Price
  • CRDL $9.00
  • BHST $13.00
  • AVG Volume (30 Days)
  • CRDL 289.4K
  • BHST 9.3K
  • Earning Date
  • CRDL 08-11-2025
  • BHST 08-15-2025
  • Dividend Yield
  • CRDL N/A
  • BHST N/A
  • EPS Growth
  • CRDL N/A
  • BHST N/A
  • EPS
  • CRDL N/A
  • BHST N/A
  • Revenue
  • CRDL N/A
  • BHST $27,704,000.00
  • Revenue This Year
  • CRDL N/A
  • BHST $116.40
  • Revenue Next Year
  • CRDL N/A
  • BHST $55.91
  • P/E Ratio
  • CRDL N/A
  • BHST N/A
  • Revenue Growth
  • CRDL N/A
  • BHST 74.76
  • 52 Week Low
  • CRDL $0.77
  • BHST $4.66
  • 52 Week High
  • CRDL $2.63
  • BHST $7.99
  • Technical
  • Relative Strength Index (RSI)
  • CRDL 56.90
  • BHST N/A
  • Support Level
  • CRDL $1.14
  • BHST N/A
  • Resistance Level
  • CRDL $1.42
  • BHST N/A
  • Average True Range (ATR)
  • CRDL 0.10
  • BHST 0.00
  • MACD
  • CRDL 0.01
  • BHST 0.00
  • Stochastic Oscillator
  • CRDL 83.33
  • BHST 0.00

About CRDL Cardiol Therapeutics Inc.

Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.

About BHST BioHarvest Sciences Inc. Common Stock

BioHarvest Sciences Inc is the developer and owner of the patented bio-cell growth platform farming technology. This company is the industrial large-scale plant cell growth technology capable of directly and constantly producing active plant ingredients without the necessity to grow the plant itself. The company is focused on leveraging its botanical synthesis technology to develop the next generation of science-based and clinical therapeutic solutions, within two business verticals - nutraceutical health and wellness products such as dietary supplements, and the development of plant cell-based Active Pharmaceutical Ingredients (APIs) that focus on specific medical indications.

Share on Social Networks: